 NEWARK, Calif., April 22, 2021 GLOBE NEWSWIRE -- Rain Therapeutics Inc. Rain, a clinical-stage company developing precision oncology therapeutics, today announced the pricing of its initial public offering of 7,352,941 shares of common stock at a public offering price of 17.00 per share. The gross proceeds to Rain from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Rain, are expected to be approximately 125.0 million. All of the shares are being offered by Rain. The shares are expected to begin trading on The Nasdaq Global Select Market on April 23, 2021 under the ticker symbol RAIN. In addition, Rain has granted the underwriters a 30-day option to purchase up to an additional 1,102,941 shares of common stock at the initial public offering price, less underwriting discounts and commissions. The offering is expected to close on April 27, 2021 subject to the satisfaction of customary closing conditions. 